These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25989503)

  • 1. Variable Use of Model for End-Stage Liver Disease Exception Points in Patients With Neuroendocrine Tumors Metastatic to the Liver and Its Impact on Patient Outcomes.
    Nobel YR; Goldberg DS
    Transplantation; 2015 Nov; 99(11):2341-6. PubMed ID: 25989503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
    Goldberg D; French B; Abt P; Feng S; Cameron AM
    Liver Transpl; 2012 Apr; 18(4):434-43. PubMed ID: 22271656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
    Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
    Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy.
    Gadiparthi C; Cholankeril G; Yoo ER; Hu M; Wong RJ; Ahmed A
    Dig Dis Sci; 2018 Jun; 63(6):1647-1653. PubMed ID: 29611079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of Waitlist Mortality in Portopulmonary Hypertension.
    DuBrock HM; Goldberg DS; Sussman NL; Bartolome SD; Kadry Z; Salgia RJ; Mulligan DC; Kremers WK; Kawut SM; Krowka MJ; Channick RN
    Transplantation; 2017 Jul; 101(7):1609-1615. PubMed ID: 28207639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of model for end-stage liver disease exceptions for donation after cardiac death graft recipients relisted for liver transplantation.
    Maduka RC; Abt PL; Goldberg DS
    Liver Transpl; 2015 Apr; 21(4):554-60. PubMed ID: 25597393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database.
    Goldberg DS; Krok K; Batra S; Trotter JF; Kawut SM; Fallon MB
    Gastroenterology; 2014 May; 146(5):1256-65.e1. PubMed ID: 24412528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of MELD exception points for hydrothorax on posttransplant mortality: a propensity score-matched analysis.
    Fathma S; Boateng S; Amatya A; Ameyaw P; Banini BA
    Eur J Gastroenterol Hepatol; 2024 Aug; 36(8):1016-1021. PubMed ID: 38829948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver transplantation for metastatic neuroendocrine tumors: Outcomes and prognostic variables.
    Sher LS; Levi DM; Wecsler JS; Lo M; Petrovic LM; Groshen S; Ji L; Uso TD; Tector AJ; Hamilton AS; Marsh JW; Schwartz ME
    J Surg Oncol; 2015 Aug; 112(2):125-32. PubMed ID: 26171686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Waitlist Outcomes for Exception and Non-exception Liver Transplant Candidates in the United States Following Implementation of the Median MELD at Transplant (MMaT)/250-mile Policy.
    Ishaque T; Beckett J; Gentry S; Garonzik-Wang J; Karhadkar S; Lonze BE; Halazun KJ; Segev D; Massie AB
    Transplantation; 2024 Aug; 108(8):e170-e180. PubMed ID: 38548691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
    Berry K; Ioannou GN
    Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Center variation in the use of nonstandardized model for end-stage liver disease exception points.
    Goldberg DS; Makar G; Bittermann T; French B
    Liver Transpl; 2013 Dec; 19(12):1330-42. PubMed ID: 24039090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation.
    Leise MD; Kim WR; Kremers WK; Larson JJ; Benson JT; Therneau TM
    Gastroenterology; 2011 Jun; 140(7):1952-60. PubMed ID: 21334338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Outcome-Based Approach to Assign MELD Exception Points for Patients With Hepatocellular Cancer.
    Kensinger CD; Feurer ID; Karp SJ
    Transplantation; 2017 Sep; 101(9):2056-2061. PubMed ID: 28471871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver Transplantation for Hepatic Epithelioid Hemangioendothelioma Is Facilitated by Exception Points With Acceptable Long-term Outcomes.
    Brahmbhatt M; Prenner S; Bittermann T
    Transplantation; 2020 Jun; 104(6):1187-1192. PubMed ID: 31577674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Associated with Survival of Patients With Severe Acute-On-Chronic Liver Failure Before and After Liver Transplantation.
    Sundaram V; Jalan R; Wu T; Volk ML; Asrani SK; Klein AS; Wong RJ
    Gastroenterology; 2019 Apr; 156(5):1381-1391.e3. PubMed ID: 30576643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
    Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
    Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional Variation in Appropriateness of Non-Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception.
    Cannon RM; Davis EG; Goldberg DS; Lynch RJ; Shah MB; Locke JE; McMasters KM; Jones CM
    J Am Coll Surg; 2020 Apr; 230(4):503-512.e8. PubMed ID: 32007535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease exception policy and outcomes in pediatric patients with hepatopulmonary syndrome requiring liver transplantation.
    Raza MH; Kwon Y; Kobierski P; Misra AC; Lim A; Goldbeck C; Etesami K; Kohli R; Emamaullee J
    Liver Transpl; 2023 Feb; 29(2):134-144. PubMed ID: 35876731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival outcomes in liver transplant recipients with Model for End-stage Liver Disease scores of 40 or higher: a decade-long experience.
    Panchal HJ; Durinka JB; Patterson J; Karipineni F; Ashburn S; Siskind E; Ortiz J
    HPB (Oxford); 2015 Dec; 17(12):1074-84. PubMed ID: 26373873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.